000766.SHE Tonghua Golden-Horse Pharmaceutical Industry Co Ltd
- Market cap
- CNY 13.3B
- P/E
- 689.5x
- P/B
- 5.76x
- ROE
- 0.1%
- Dividend yield
- 0.61%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 000766.SHE undervalued?
Graham numberThe Graham number of Tonghua Golden-Horse Pharmaceutical Industry Co Ltd cannot be estimated reliably (the estimate is too far from the market price).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Tonghua Golden-Horse Pharmaceutical Industry Co Ltd fundamental analysis
No fundamental analysis for Tonghua Golden-Horse Pharmaceutical Industry Co Ltd yet.
Tonghua Golden-Horse Pharmaceutical Industry Co Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Tonghua Golden-Horse Pharmaceutical Industry Co Ltd
Tonghua Golden-Horse Pharmaceutical Industry Co,Ltd., together with its subsidiaries, engages in the research, development, manufacture, and sale of pharmaceutical products in China. The company provides anti-tumor drugs, gynecological medications, medication for rheumatic bone pain, urological medications, heat-clearing and detoxifying drugs, cardiovascular and cerebrovascular drugs, digestive medications, tonifying and restorative medicines, respiratory medication, diabete…
Full company profileTonghua Golden-Horse Pharmaceutical Industry Co Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Tonghua Golden-Horse Pharmaceutical Industry Co Ltd annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 850M | 1.52B | 2.09B | 1.98B | 1.11B | 1.52B | 1.47B | 1.47B | 1.32B | 1.17B | 982M |
| Gross Profit | 585M | 1.20B | 1.76B | 1.63B | 882M | 1.17B | 1.12B | 1.09B | 994M | 844M | 723M |
| Operating Income | 233M | 300M | 408M | -2.01B | -357M | 62.3M | 51.4M | 51.7M | 67.4M | 121M | 101M |
| EBITDA | 271M | 343M | 361M | 112M | -279M | 183M | 193M | 196M | 205M | 187M | 94.1M |
| Net Income | 213M | 258M | 331M | -2.04B | -359M | 35.3M | 30.2M | 43.9M | 56.4M | 34.3M | 2.63M |
| EPS | 0.23 | 0.27 | 0.34 | -2.11 | -0.37 | 0.04 | 0.03 | 0.05 | 0.06 | 0.04 | 0.00 |
| Balance Sheet | |||||||||||
| Total Assets | 5.30B | 5.73B | 5.96B | 4.70B | 4.98B | 4.64B | 4.69B | 4.52B | 4.48B | 4.48B | 4.62B |
| Total Liabilities | 1.14B | 1.31B | 1.25B | 2.03B | 2.68B | 2.30B | 2.32B | 2.20B | 2.23B | 2.17B | 2.31B |
| Shareholders' Equity | 4.12B | 4.38B | 4.67B | 2.63B | 2.27B | 2.31B | 2.34B | 2.32B | 2.26B | 2.31B | 2.31B |
| Cash & Short-term Investments | 472M | 626M | 336M | 289M | 601M | 302M | 337M | 178M | 275M | 272M | 469M |
| Total Debt | 356M | 591M | 477M | 1.11B | 1.94B | 228M | 1.59B | 1.69B | 198M | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 90.6M | 26.4M | 171M | 74.9M | 80.7M | 138M | 198M | 113M | 163M | 105M | - |
| Capital Expenditure | 169M | 118M | 74.4M | 61.0M | 19.2M | 25.5M | 23.7M | 26.7M | 49.2M | 64.1M | 8.80M |
| Free Cash Flow | -78.8M | -91.7M | 96.3M | 13.9M | 61.5M | 113M | 174M | 86.1M | 114M | 41.0M | 65.7M |
| Ratios | |||||||||||
| ROE | 5.2% | 5.9% | 7.1% | -77.6% | -15.8% | 1.5% | 1.3% | 1.9% | 2.5% | 1.5% | 0.1% |
| ROA | 4.0% | 4.5% | 5.6% | -43.5% | -7.2% | 0.8% | 0.6% | 1.0% | 1.3% | 0.8% | 0.1% |
| Net Profit Margin | 25.1% | 17.0% | 15.8% | -103.3% | -32.3% | 2.3% | 2.1% | 3.0% | 4.3% | 2.9% | 0.3% |
| Debt to Equity | 0.09x | 0.13x | 0.10x | 0.42x | 0.86x | 0.10x | 0.68x | 0.73x | 0.09x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Tonghua Golden-Horse Pharmaceutical Industry Co Ltd dividends
- Dividend yield
- 0.61%
- Forward dividend
- -
- Payout ratio
- 237.2%
- Ex-dividend date
- May 25, 2001
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 81.3M | 0.08 | 237.2% |
| 2024 | CNY 85.0M | 0.09 | 150.6% |
| 2023 | CNY 83.3M | 0.09 | 189.7% |
| 2022 | CNY 88.6M | 0.09 | 293.9% |
| 2021 | CNY 97.5M | 0.10 | 276.4% |
| 2020 | CNY 131M | 0.14 | - |
| 2019 | CNY 42.4M | 0.04 | - |
| 2018 | CNY 24.9M | 0.03 | 7.5% |
| 2017 | CNY 26.4M | 0.03 | 10.2% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1.5:1 on May 25, 2001.
Who owns Tonghua Golden-Horse Pharmaceutical Industry Co Ltd
- Insiders 36.78%
- Institutions 3.64%
- Public & others 59.58%
- Shares outstanding 966M
- Free float 702M
Tonghua Golden-Horse Pharmaceutical Industry Co Ltd company profile
- Company name
- Tonghua Golden-Horse Pharmaceutical Industry Co Ltd
- Ticker
- 000766.SHE
- ISIN
- CNE000000735
- Exchange
- Shenzhen Stock Exchange
- Listed since
- Apr 18, 1997
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 1,480
- Fiscal year end
- December
- Address
- No. 999, Jinma Road, Tonghua, China, 134003
- Phone
- 86 40 0642 8777
- Website
- thjm.cn
About Tonghua Golden-Horse Pharmaceutical Industry Co Ltd
Tonghua Golden-Horse Pharmaceutical Industry Co,Ltd., together with its subsidiaries, engages in the research, development, manufacture, and sale of pharmaceutical products in China. The company provides anti-tumor drugs, gynecological medications, medication for rheumatic bone pain, urological medications, heat-clearing and detoxifying drugs, cardiovascular and cerebrovascular drugs, digestive medications, tonifying and restorative medicines, respiratory medication, diabetes medication, ENT medication, and pediatric medications. It also offers Xiaojin pills, Tian Ranshexiang Xiaojin pills, Xiaokechuan capsules, Jiuwei Qianghuo granules, Xiongdan powder, Bear Bile powder, and Wenweishu tablets to treat glandular hyperplasia, inflammatory diseases, bone trauma and soft tissue injury, and other related diseases. In addition, the company provides bacillus cereus live bacteria capsules, bacillus cereus live bacteria tablets are therapeutic live bacteria microecological preparations to treat enteritis, diarrhea, infantile diarrhea, and intestinal dysfunction. The company was founded in 1990 and is headquartered in Tonghua, China.
Tonghua Golden-Horse Pharmaceutical Industry Co Ltd management
7- Mr. Yufu ZhangGM & Chairman · born 1962
- Mr. Jun YuDeputy GM & CFO · born 1971
- Mr. Yu JingDeputy GM & Non-Independent Director · born 1979
- Mr. Hailong ZhangExecutive Vice President · born 1963
- Mr. Weilin JiaBoard Secretary · born 1965
- Mr. Xiaolang YuDeputy General Manager · born 1970
- Lan GengAccounting Supervisor